Plus Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTV research report →
Companywww.plustherapeutics.com
Plus Therapeutics, Inc. , a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
- CEO
- Marc H. Hedrick
- IPO
- 2001
- Employees
- 21
- HQ
- Austin, TX, US
Price Chart
Valuation
- Market Cap
- $15.56M
- P/E
- -3.58
- P/S
- 3.00
- P/B
- 3.57
- EV/EBITDA
- -1.58
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.80%
- Op Margin
- -364.36%
- Net Margin
- -230.24%
- ROE
- -198.48%
- ROIC
- -148.83%
Growth & Income
- Revenue
- $5.21M · -10.49%
- Net Income
- $-22,386,000 · -72.49%
- EPS
- $-7.19 · 85.25%
- Op Income
- $-15,298,000
- FCF YoY
- -94.79%
Performance & Tape
- 52W High
- $23.50
- 52W Low
- $2.90
- 50D MA
- $5.80
- 200D MA
- $10.85
- Beta
- 1.40
- Avg Volume
- 324.90K
Get TickerSpark's AI analysis on PSTV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | van Es-Johansson An | other | 3,686 |
| May 14, 26 | van Es-Johansson An | other | 3,686 |
| May 14, 26 | Hawkins Richard J | other | 3,686 |
| May 14, 26 | Hawkins Richard J | other | 3,686 |
| May 14, 26 | Guse Kyle | other | 3,686 |
| May 14, 26 | Guse Kyle | other | 3,686 |
| May 14, 26 | Clowes Howard | other | 3,686 |
| May 14, 26 | Clowes Howard | other | 3,686 |
| May 14, 26 | ANDREWS RONALD ASBURY | other | 3,686 |
| May 14, 26 | ANDREWS RONALD ASBURY | other | 3,686 |
Our PSTV Coverage
We haven't published any research on PSTV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PSTV Report →